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Summary
Gastric neuroendocrine neoplasms (GNENs) are classified into three types according to their aetiology. We present a 
clinical case of a female patient of 66 years and a well-differentiated (grade 2), type 3 GNEN with late liver metastasis 
(LM). The patient underwent surgical excision of a gastric lesion at 50 years of age, without any type of follow-up. Sixteen 
years later, she was found to have a neuroendocrine tumour (NET) metastatic to the liver. The histological review of the 
gastric lesion previously removed confirmed that it was a NET measuring 8 mm, pT1NxMx (Ki67 = 4%). 68Ga-DOTANOC 
PET/CT reported two LM and a possible pancreatic tumour/gastric adenopathy. Biopsies of the lesion were repeatedly 
inconclusive. She had a high chromogranin A, normal gastrin levels and negative anti-parietal cell and intrinsic factor 
antibodies, which is suggestive of type 3 GNEN. She underwent total gastrectomy and liver segmentectomies (segment IV 
and VII) with proven metastasis in two perigastric lymph nodes and both with hepatic lesions (Ki67 = 5%), yet no evidence 
of local recurrence. A 68Ga-DOTANOC PET/CT was performed 3 months after surgery, showing no tumour lesions and 
normalisation of CgA. Two years after surgery, the patient had no evidence of disease. This case illustrates a rare situation, 
being a type 3, well-differentiated (grade 2) GNEN, with late LM. Despite this, it was possible to perform surgery with 
curative intent, which is crucial in these cases, as systemic therapies have limited efficacy. We emphasise the need for 
extended follow-up in these patients.
Background
Gastric neuroendocrine neoplasms (GNENs) represent 
about 7% of all digestive NET, with a prevalence rate 
of 35/100  000 (1, 2). According to the 2010 World 
Health Organization classification, they may present 
as neuroendocrine tumours (NETs) with Ki67 ≤2% 
(Grade 1 – G1), 3–20% (Grade 2 – G2) or neuroendocrine 
carcinoma (NEC) with Ki67 >20% (Grade G3) (1).
GNENs may be classified into three types, according 
to their aetiology: type 1 is associated with autoimmune 
atrophic gastritis, and it has the lowest metastatic potential 
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Learning points:
 • GNENs have a very heterogeneous biological behaviour.
 • Clinical distinction between the three types of GNEN is essential to plan the correct management strategy.
 • LMs are rare and more common in type 3 and grade 3 GNEN.
 • Adequate follow-up is crucial for detection of disease recurrence.
 • Curative intent surgery is the optimal therapy for patients with limited and resectable LM, especially in well-
differentiated tumours (grade 1 and 2).
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from all three types; type 2 is histologically similar to type 
1 but is associated with gastrinomas (Zollinger–Ellison 
syndrome), usually as part of MEN1 syndrome; type 3 is 
sporadic, without hypergastrinaemia or a gastric condition 
as predisponent factors. Type 3 lesions are larger and often 
accompanied by lymph node and distant metastases, 
resulting in a poor prognosis (1, 2, 3, 4, 5). Serum gastrin 
levels are crucial on determining the GNEN subgroup, 
i.e. type 3 GNEN is non-gastrin dependent, unlike type 1 
and 2 GNEN. It is essential to obtain an adequate clinical, 
biochemical and pathological assessment of the tumour 
in order to plan the correct management strategy, as each 
of the 3 GNEN types have distinct biological behaviour 
and prognosis (2, 3).
The most common NEN with LM are pancreatic and 
small bowel NET. There is sparse data on the prevalence 
of LM in GNEN, although it is estimated that it rarely 
occurs in these patients and they are mostly synchronous 
(Table 1). At the time of the LM diagnosis, only 20–30% 
may still have the chance for curative intent surgery (5).
Well-differentiated, type 3 GNEN are rare, as only 
two other cases are reported in medical literature (6). 
Also, liver involvement is unusual in GNEN patients 
and only 25% develop during disease course, which was 
the case for this patient. LM are more common in NETs 
with higher proliferation index (grade 3) and in type 3 
GNEN, but this patient had a grade 2 lesion, which might 
explain the relatively indolent course of the disease (7, 8). 
In addition, the patient was able to have curative intent 
surgery, which is relatively uncommon in cases of NETs 
with LM metastases.
Case presentation
A 66-year-old female patient complained of epigastralgy, 
nausea and anorexia for 3  months. An abdominal 
ultrasound and CT were performed, which reported two 
hepatic lesions in segments IV (3.5 cm) and VII (2 cm) and 
a lesion between the pancreas and the stomach (4.3 cm). 
Liver biopsy revealed LM of a grade 2 NET (Ki67 = 10%). She 
was then sent to our department for further investigation 
and treatment.
Investigation
Anamnesis revealed that she had a gastric lesion excised 
16 years previously but she did not know the histological 
result. Previous medical records showed that the gastric 
lesion was a NET and the histological review confirmed 
that the primary tumour was indeed a NET measuring 
8 mm, pT1NxMx (Ki67 = 4%).
68Ga-DOTANOC PET/CT reported two liver metastases 
and a lesion between the stomach and pancreas, which 
was thought to be a possible pancreatic tumour/gastric 
adenopathy (Fig. 1). Biopsies of the lesion were repeatedly 
inconclusive. She had a high chromogranin A (CgA 
– 5685 ng/mL – normal range: <102 ng/mL), with no 
signs of pernicious anaemia (haemoglobin of 13.1 g/dL; 
normal mean corpuscular volume and mean corpuscular 
haemoglobin concentration). She also had normal 
gastrin levels and negative anti-parietal cell antibodies 
and anti-intrinsic factor antibodies. A gastric mapping 
was performed and the histological report on the gastric 
biopsies showed no signs of glandular atrophy or areas of 
intestinal metaplasia.
Treatment
As the liver lesions were thought to be metastasis from 
a GNEN excised 16  years before and the perigastric 
lesion was thought to be a lymph node metastasis, 
the patient underwent total gastrectomy and liver 
segmentectomies (segment IV and VII). Histological 
report on the LM confirmed metastasis in two perigastric 
lymph nodes and both hepatic lesions (Ki67 = 5%), with 
positive staining for chromogranin and synaptophysin. 
The histological report on the stomach revealed mild 
glandular atrophy, but no areas of intestinal metaplasia 
Table 1 Classification of GNEN (1).
GNEN Type 1 Type 2 Type 3
Prevalence (%) 70–80 5–6 14–23
Characteristics 1–2 cm; multiple lesions Isolated lesion (>2 cm); ulcerated
Grade G1 G1–2 G3
Associated condition Autoimmune atrophic gastritis Gastrinoma/MEN 1 –
Gastrin levels Elevated Elevated Normal
Gastric pH Elevated Low Normal
Metastases (%) 2–5 10–30 50–100
Mortality (%) 0–1 <10 25–30
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or inflammation of the lamina propria and no evidence 
of local recurrence.
Outcome and follow-up
A 68Ga-DOTANOC PET/CT was performed 3 months after 
surgery, showing that the patient had no tumour lesions 
(Fig. 2). Thoracic-abdominal-pelvic CT scan done every 
6 months showed no signs of disease recurrence and CgA 
levels are within normal range (69.6 ng/mL).
Discussion
GNENs have a very heterogeneous biological behaviour. 
Type 1 and 2 GNENs have a relatively benign clinical 
course, and the treatment strategy is focused on lesion 
resection and endoscopic follow-up. On the other hand, 
type 3 is usually associated with a higher proliferative 
index (grade 3), and therefore, a higher metastatic 
rate (50–100%). It may mimic the course of gastric 
adenocarcinoma and their treatments plans are identical 
(1). It is usually a solitary lesion, sporadic, and it is often 
associated with pain, anorexia and weight loss, as was the 
case with this patient.
This case was classified as a type 3 sporadic GNEN, 
as the patient had no hypergastrinaemia or autoimmune 
atrophic gastritis as predisponent factors. Despite the 
histological report on the stomach revealing mild 
glandular atrophy (but no areas of intestinal metaplasia), 
the patient showed no signs of pernicious anaemia, along 
with normal gastrin levels and negative anti-parietal cell 
antibodies and anti-intrinsic factor antibodies.
Furthermore, this is an uncommon situation because, 
despite being a sporadic GNEN, which would imply a 
worst outcome, it was classified as well-differentiated 
grade 2 GNEN. In addition, liver involvement is rarely 
observed in patients with GNENs and the majority 
of these cases have a high Ki67 and only 25% develop 
during disease course (7, 8). This is a very unusual case 
and only two other cases of well-differentiated type 3 
GNENs are reported in medical literature (6). In one of 
the cases, the patient had a 10 cm GNEN (Ki67 = 7%), with 
no metastasis on diagnosis. On the other case, the patient 
had a 4 cm GNEN (Ki67 = 7%) with bilateral synchronous 
ovarian metastasis. Both cases highlight the biological 
heterogeneity of NETs, as they had the same Ki67 index, 
but different outcomes regarding disease dissemination.
The management of NET LM depends on its 
distribution. According to the ENETS Consensus 
Guidelines for the Management of Patients with Liver 
and Other Distant Metastases from Neuroendocrine 
Neoplasms, there are three distinct patterns of liver 
infiltration by metastases and each one has a specific 
therapeutic approach: (i) liver metastases confined 
to one liver lobe or limited to two adjacent segments 
that can be resected by a standard anatomical resection 
(20–25% of the cases); (ii) LM found in one lobe primarily 
but with smaller satellites contralaterally (10–15% of 
Figure 1
68Ga-DOTANOC PET/CT reported two liver 
metastases and a lesion between the stomach 
and pancreas, which was thought to be a possible 
pancreatic tumour/gastric adenopathy.
Figure 2
68Ga-DOTANOC PET/CT performed 3 months after 
surgery showed no tumour lesions.
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the cases) and can still be handled surgically, including 
ablative approaches and (iii) diffuse, multifocal liver 
metastases (60–70% of the cases) that should not be 
treated surgically (9).
In this case, the two LMs were not located in adjacent 
segments, but the multidisciplinary team considered that 
this patient still had limited and resectable tumour burden. 
Therefore, the team recommended surgical resection. For 
patients with LM who are ineligible for complete resection, 
there are a variety of locally ablative procedures such as 
thermal ablative techniques, transarterial embolisation 
or chemoembolisation and radioembolisation. Other 
medical therapies include peptide receptor radionuclide 
therapy, somatostatin analogues and chemotherapy. 
However, there is very few evidence regarding the 
effectiveness of systemic treatment in patients with well-
differentiated, type 3 GNEN. Therefore, surgery with 
curative intent is the most important treatment option 
in these cases and is associated with better long-term 
outcomes (9, 10). Alongside tumour grade, LM represents 
one of the most powerful predictors of survival (3, 4, 5, 7). 
Despite having a high likelihood of disease recurrence, the 
multidisciplinary team decided not to pursue any further 
adjuvant treatments, given that there is no evidence 
regarding its effectiveness. For that reason, it was decided 
to keep an active surveillance strategy, with clinical, 
imagiological and biochemical follow-up. The patient has 
been seen regularly and shows, thus far, no evidence of 
disease recurrence.
An adequate follow-up would perhaps be able to make 
a timely diagnosis of disease recurrence and enable the 
possibility of limited surgery. Type 3 GNENs have a higher 
risk of disease recurrence, and this should have prompted 
a prolonged follow-up. However, this is an uncommon 
case and there is no current evidence on which type of 
follow-up plan should be performed.
For biochemical follow-up, using chromogranin A 
as our tumour marker would be useful. Despite being 
relatively unspecific, it would have helped detect early 
disease recurrence as it was high when the patient was 
diagnosed with LM, and it normalised after liver surgery. 
Gastric endoscopy is regarded as a useful examination 
for follow-up of GNEN, but in this case, it did not detect 
disease recurrence. Endoscopic ultrasound, however, 
may have detected gastric adenopathies. Imaging 
examinations, such as thoracic-abdominal and pelvic 
CT, are crucial for the follow-up of cases like this one, 
with considerable risk of recurrence. On the other hand, 
given that this is a grade 2 tumour, with an indolent 
clinical course, the time span between imaging exams is 
controversial. A 68Ga-DOTANOC PET/CT would probably 
be recommended due to its high sensitivity regarding the 
diagnosis of metastasis and would complement this case, 
if any of the other imaging tests suggested the possibility 
of recurrence. After a few years beyond surgery, abdominal 
CT might be performed instead, as disease recurrence is 
more common in the liver and abdominal lymph nodes.
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